Compare CREG & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CREG | NNVC |
|---|---|---|
| Founded | N/A | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 24.4M |
| IPO Year | N/A | N/A |
| Metric | CREG | NNVC |
|---|---|---|
| Price | $1.20 | $1.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 87.0K | ★ 294.9K |
| Earning Date | 02-14-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $173,659.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.93 | $0.94 |
| 52 Week High | $14.70 | $2.23 |
| Indicator | CREG | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 45.13 | 39.32 |
| Support Level | $1.16 | $1.13 |
| Resistance Level | $1.34 | $1.16 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 19.34 | 7.32 |
Smart Powerr Corp is a pioneer in waste energy recycling and a developer of energy efficiency solutions for various energy-intensive industries in China. It uses the Build-Operate-Transfer (BOT) model to provide energy-saving and recovery facilities for multiple energy-intensive industries in China. Its waste energy recycling projects allow customers which use substantial amounts of electricity to recapture previously wasted pressure, heat, and gas from their manufacturing processes to generate electricity. The company offers waste energy recycling systems to companies for use in nonferrous metal plants. It constructs its projects at its customer's facility and the electricity produced is used on-site by the customer.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.